ClinicalTrials.gg
CompletedNCT05499130RELIEVE UCCDUpdated Mar 27, 2026Results posted

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Phase 2 interventional study of TEV-48574 and Placebo in Crohn Disease and Colitis, Ulcerative, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 164 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14.

Secondary objectives:

  • To evaluate the efficacy of 2 different doses of TEV-48574 as assessed by multiple standard measures
  • To evaluate the safety and tolerability of 2 different doses of TEV-48574
  • To evaluate the immunogenicity of 2 different dioses of TEV-48574

The study will consist of a screening period of up to 6 weeks (42 days), a 14-week treatment period, and a 4-week follow-up period.

02

Conditions studied

  • Crohn Disease
  • Colitis, Ulcerative
03

In context

Crohn Disease

1,992 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

This study's enrollment of 290 is above the median of 67 across 1,260 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Ulcerative Colitis (UC) or Crohn's Disease (CD) for ≥3 months
  • The participant is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study
  • The participant is able to understand the nature of the study and any potential hazards associated with participating in the study
  • Women of non- who are either surgically (documented hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or congenitally sterile as assessed by a physician, or 1-year
  • Male participants (including vasectomized) with women of childbearing potential (WOCBP) partners (whether pregnant or not) must use condoms after the first medicinal product (IMP) administration and throughout the study or until 50 days after the last IMP dose, whichever is longer

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The participant has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the participant at increased risk during the study as judged by the investigator and/or the clinical study physician
  • Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic coliti
  • Participant has colonic dysplasia or neoplasia, toxic megacolon, primary sclerosing cholangitis, known non-passable colonic stricture, presence of colonic or small bowel stoma, presence of non-passable colonic or small bowel obstruction or resection preventing the endoscopy procedure, or fulminant colitis
  • Presence of active enteric infections (positive stool culture) or a history of serious infection (requiring parenteral antibiotic and/or hospitalization) within 4 weeks prior to the first screening visit
  • Participant anticipates requiring major surgery during this study.
  • A participant is core antibody or surface antigen positive and/or antibody positive with detectable ribonucleic acids, or positive types 1 or 2 at screening.
  • A history of an opportunistic infection (eg, cytomegalovirus retinitis, Pneumocystis carinii, or aspergillosis)
  • A history of more than 2 herpes zoster episode in the last 5 years or multimetameric herpes zoster
  • A history of or ongoing chronic or recurrent serious infectious disease (eg, infected indwelling prosthesis or osteomyelitis)
  • The participant is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study.
  • Presence of a transplanted organ
  • A history of within the last 5 years (exception: basal cell carcinoma or in situ carcinoma of the cervix if successful curative therapy occurred at least 12 months prior to screening) or curatively resected papillary thyroid cance
  • Current or history (within 2 years) of serious psychiatric disease or alcohol or drug abuse
  • Participants with incurable diseases, persons in nursing homes, and participants incapable of giving written

NOTE- Additional criteria apply, please contact the investigator for more information

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    TEV-48574, 450 mg (UC)

    Administered by subcutaneous infusion for participants with UC

    Drug: TEV-48574

  • Experimental
    TEV-48574, 900 mg (UC)

    Administered by subcutaneous infusion for participants with UC

    Drug: TEV-48574

  • Experimental
    TEV-48574, 1800 mg (UC)

    Administered by subcutaneous infusion for participants with UC. This arm was discontinued with Amend 03.

    Drug: TEV-48574

  • Experimental
    TEV-48574, 450 mg (CD)

    Administered by subcutaneous infusion for participants with CD

    Drug: TEV-48574

  • Experimental
    TEV-48574, 900 mg (CD)

    Administered by subcutaneous infusion for participants with CD

    Drug: TEV-48574

  • Experimental
    TEV-48574, 1800 mg (CD)

    Administered by subcutaneous infusion for participants with CD. This arm was discontinued with Amend 03.

    Drug: TEV-48574

  • Placebo comparator
    Placebo UC

    Matching Placebo

    Drug: Placebo

  • Placebo comparator
    Placebo CD

    Matching Placebo

    Drug: Placebo

Interventions

  • Subcutaneous infusion

    Also known as: duvakitug

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS

    The MMS is a tool designed to measure disease activity for UC. It consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review. Each subscore was graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total MMS ranging from 0 (normal or inactive disease) to 9 (severe disease), where higher scores indicated more severe disease activity. Clinical remission was defined as MMS ≤2 points with Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and centrally read endoscopic score of 0 or 1, where a score of 1 did not include "friability".

    Time frame: Week 14

  2. Number of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CD

    The SES-CD assessed the degree of inflammation. The SES-CD assesses the following 4 components: presence of ulcers, percentage of ulcerated surfaces, affected surface, and presence of strictures. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components was assessed in the 5 segments: the rectum, sigmoid and left colon, transverse colon, right colon, and ileum. The SES-CD was the sum of the individual scores of each of the components across the 5 segments. The range of SES-CD scores was 0 (none) - 12 (severe) for each segment, and 0 (none) - 60 (severe) for the overall SES-CD score, with larger scores indicating greater degree of inflammation. Endoscopic response at Week 14 in participants with moderate to severe CD was defined as a reduction in SES-CD of at least 50% from baseline.

    Time frame: Baseline to Week 14

Secondary outcomes

  1. Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by the MMS

    The MMS is a tool designed to measure disease activity for UC. It consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review. Each subscore was graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total MMS ranged from 0 (normal or inactive disease) to 9 (severe disease), where higher scores indicated more severe disease activity. Clinical response was defined as a decrease from baseline in the MMS of at least 2 points and at least a 30% reduction from baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of ≤1.

    Time frame: Baseline to Week 14

  2. Number of Participants With Moderate to Severe UC With Endoscopic Improvement as Defined by the Mayo Endoscopic Subscore (MES)

    The endoscopic subscore evaluation for the MMS consisted of independent, blinded, central review of a high-resolution recorded video. The endoscopic subscore assessed disease activity from 0 (normal or inactive disease) to 3 (severe activity). Higher scores indicated more severe disease activity. Endoscopic improvement was defined as a MES of 0 or 1 at Week 14.

    Time frame: Week 14

  3. Number of Participants With Moderate to Severe UC With Endoscopic Remission as Defined by the MES

    The endoscopic subscore evaluation for the MMS consisted of independent, blinded, central review of a high-resolution recorded video. The endoscopic subscore assessed disease activity from 0 (normal or inactive disease) to 3 (severe activity). Higher scores indicated more severe disease activity. Endoscopic remission was defined as a MES of 0 at Week 14.

    Time frame: Week 14

  4. Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by 2-item Patient-reported Outcome (PRO2) Score

    The PRO2-UC score was derived from 2 parameters from the MMS: stool frequency and rectal bleeding, recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Each parameter ranged from 0 (normal) to 3 (severe) with each subscore representing an average over the preceding 7 days. The total score was the summation of the subscores and therefore ranged from 0 (normal or inactive disease) to 6 (severe activity), where higher scores indicated more severe disease activity. Clinical response was defined as decrease from baseline of at least 50% in PRO2 (stool frequency and rectal bleeding) at Week 14.

    Time frame: Baseline to Week 14

  5. Number of Participants With Moderate to Severe UC With a Clinical Remission as Defined by PRO2 Score

    The PRO2-UC score was derived from 2 parameters from the MMS: stool frequency and rectal bleeding, recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Each parameter ranged from 0 (normal) to 3 (severe) with each subscore representing an average over the preceding 7 days. The total score was the summation of the subscores and therefore ranged from 0 (normal or inactive disease) to 6 (severe activity), where higher scores indicated more severe disease activity. Clinical remission was defined as score of stool frequency = 0 and rectal bleeding = 0 on the PRO2 scale at Week 14.

    Time frame: Week 14

  6. Number of Participants With Moderate to Severe CD With an Endoscopic Response as Defined by the Modified Multiplier-Simple Endoscopic Score (MM-SES-CD)

    The MM-SES-CD is an endoscopic scoring tool that considers each individual parameter's prognostic value for achieving endoscopic remission while on active therapy. The SES-CD assesses the following 4 components: presence of ulcers, percentage of ulcerated surfaces, affected surface, and presence of strictures. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components was assessed in the 5 segments: the rectum, sigmoid and left colon, transverse colon, right colon, and ileum. The SES-CD was the sum of the individual scores of each of the components across the 5 segments. The range of SES-CD scores was 0 (none) - 12 (severe) for each segment, and 0 (none) - 60 (severe) for the overall SES-CD score, with higher scores indicating a greater degree of inflammation. Endoscopic response was defined as a decrease in MM-SES-CD of ≥50% from baseline at Week 14.

    Time frame: Baseline to Week 14

  7. Number of Participants With Moderate to Severe CD With a Clinical Response as Defined by Crohn's Disease Activity Index (CDAI) Score

    The CDAI score consisted of an adjusted composite sum of 8 parameters, including daily diary evaluation for severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight, and hematocrit. The subscores of abdominal pain (0 \[no pain\] to 3 \[worst pain\]), general well-being (0 \[well\] to 4 \[terrible\]), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score that ranged from 0 (none) to 600 (severe) with a higher score indicating a worse outcome. Clinical response was defined as a ≥100-point decrease in CDAI score from baseline.

    Time frame: Baseline to Weeks 4, 8, 12 and 14

  8. Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by CDAI Score

    The CDAI score consisted of an adjusted composite sum of 8 parameters, including daily diary evaluation for severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight, and hematocrit. The subscores of abdominal pain (0 \[no pain\] to 3 \[worst pain\]), general well-being (0 \[well\] to 4 \[terrible\]), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score that ranged from 0 (none) to 600 (severe) with a higher score indicating a worse outcome. Clinical remission was defined as a CDAI score \<150 at Week 14.

    Time frame: Week 14

  9. Number of Participants With Moderate to Severe CD With a Clinical Response as Defined by PRO2-CD Score

    The PRO2-CD score was the sum of the daily stool frequency subscore (0 \[normal\] to 3 \[severe\]) and abdominal pain subscore (0 \[no pain\] to 3 \[worst pain\]) from the CDAI. Total PRO2-CD score ranged from 0 (normal) - 6 (severe), with higher scores indicating more severe disease. These were recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Clinical response was defined as a decrease from baseline of at least 50% in PRO2-CD (abdominal pain and stool frequency) at Week 14.

    Time frame: Baseline to Week 14

  10. Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by PRO2-CD Score

    The PRO2-CD score was the sum of the daily stool frequency subscore (0 \[normal\] to 3 \[severe\]) and abdominal pain subscore (0 \[no pain\] to 3 \[worst pain\]) from the CDAI. Total PRO2-CD score ranged from 0 (normal) - 6 (severe), with higher scores indicating more severe disease. These were recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Clinical remission was defined as abdominal pain ≤1 and stool frequency ≤3 on the PRO2-CD scale at Week 14

    Time frame: Week 14

  11. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered TEAEs if onset occurred on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline (Day 1) up to Week 18

  12. Number of Participants Who Stopped Taking the Investigational Medicinal Product (IMP) Due to AEs

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline (Day 1) up to Week 18

  13. Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs)

    Treatment-emergent ADA positive: - the participant had a positive ADA sample (after first dose of study drug) but not at baseline (prior to first dose of study drug), or - the participant had a positive ADA sample at baseline (prior to first dose of study drug) and at the visit (after first dose of study drug), with at least a 4-fold increase in titer level.

    Time frame: Weeks 2, 4, 8, 14, and 18

  14. Number of ADA Positive Participants With the Presence of Neutralizing ADA

    Treatment-emergent ADA positive: - the participant had a positive ADA sample (after first dose of study drug) but not at baseline (prior to first dose of study drug), or - the participant had a positive ADA sample at baseline (prior to first dose of study drug) and at the visit (after first dose of study drug), with at least a 4-fold increase in titer level.

    Time frame: Weeks 2, 4, 8, 14, and 18

07

Results

Posted Dec 5, 2025
Limitations and caveats
The treatment arm TEV-48574 1800 mg was discontinued. Therefore, the participants randomized to TEV-48574 1800 mg arm were not included in the overall efficacy analysis for the trial (mITT Analysis Set).

Participant flow

In this trial, 290 participants were randomized, and 286 participants were analyzed; 4 randomized participants (2 ulcerative colitis \[UC\] and 2 crohn's disease \[CD\]) were excluded from all analyses for non-compliance with Good Clinical Practice.

Participant flow — Overall Study
MilestonePlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Started44474674646473
Received at least 1 dose of study drug44474674646463
Mitt analysis set44474604646460
Immunogenicity analysis set047457046463
Completed39474573737433
Not completed50109940
Withdrew: Adverse event20101410
Withdrew: Lack of efficacy10005010
Withdrew: Withdrawal by subject20001200
Withdrew: Lost to follow-up00000200
Withdrew: Other than specified00001120
Withdrew: Protocol violation00001000

Outcome measures

PrimaryNumber of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS

The MMS is a tool designed to measure disease activity for UC. It consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review. Each subscore was graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total MMS ranging from 0 (normal or inactive disease) to 9 (severe disease), where higher scores indicated more severe disease activity. Clinical remission was defined as MMS ≤2 points with Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and centrally read endoscopic score of 0 or 1, where a score of 1 did not include "friability".

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS91722
Statistical analysis
  • Placebo (UC) vs TEV-48574 450 mg (UC) · Difference in response rate: 15.7
  • Placebo (UC) vs TEV-48574 450 mg (UC) · Posterior probability: 0.949A beta-binomial model was employed to obtain this posterior probability using a non-informative prior to assess superior efficacy compared to placebo.
  • Placebo (UC) vs TEV-48574 900 mg (UC) · Difference in response rate: 27.4
  • Placebo (UC) vs TEV-48574 900 mg (UC) · Posterior probability: 0.997A beta-binomial model was employed to obtain this posterior probability using a non-informative prior to assess superior efficacy compared to placebo.
PrimaryNumber of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CD

The SES-CD assessed the degree of inflammation. The SES-CD assesses the following 4 components: presence of ulcers, percentage of ulcerated surfaces, affected surface, and presence of strictures. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components was assessed in the 5 segments: the rectum, sigmoid and left colon, transverse colon, right colon, and ileum. The SES-CD was the sum of the individual scores of each of the components across the 5 segments. The range of SES-CD scores was 0 (none) - 12 (severe) for each segment, and 0 (none) - 60 (severe) for the overall SES-CD score, with larger scores indicating greater degree of inflammation. Endoscopic response at Week 14 in participants with moderate to severe CD was defined as a reduction in SES-CD of at least 50% from baseline.

Time frame:
Baseline to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CD
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Number of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CD61222
Statistical analysis
  • Placebo (CD) vs TEV-48574 450 mg (CD) · Difference in response rate: 13.0
  • Placebo (CD) vs TEV-48574 450 mg (CD) · Posterior probability: 0.939A beta-binomial model was employed to obtain this posterior probability using a non-informative prior to assess superior efficacy compared to placebo.
  • Placebo (CD) vs TEV-48574 900 mg (CD) · Difference in response rate: 34.8
  • Placebo (CD) vs TEV-48574 900 mg (CD) · Posterior probability: 1.000A beta-binomial model was employed to obtain this posterior probability using a non-informative prior to assess superior efficacy compared to placebo.
SecondaryNumber of Participants With Moderate to Severe UC With a Clinical Response as Defined by the MMS

The MMS is a tool designed to measure disease activity for UC. It consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review. Each subscore was graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total MMS ranged from 0 (normal or inactive disease) to 9 (severe disease), where higher scores indicated more severe disease activity. Clinical response was defined as a decrease from baseline in the MMS of at least 2 points and at least a 30% reduction from baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of ≤1.

Time frame:
Baseline to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by the MMS
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by the MMS233832
SecondaryNumber of Participants With Moderate to Severe UC With Endoscopic Improvement as Defined by the Mayo Endoscopic Subscore (MES)

The endoscopic subscore evaluation for the MMS consisted of independent, blinded, central review of a high-resolution recorded video. The endoscopic subscore assessed disease activity from 0 (normal or inactive disease) to 3 (severe activity). Higher scores indicated more severe disease activity. Endoscopic improvement was defined as a MES of 0 or 1 at Week 14.

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC With Endoscopic Improvement as Defined by the Mayo Endoscopic Subscore (MES)
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC With Endoscopic Improvement as Defined by the Mayo Endoscopic Subscore (MES)102123
SecondaryNumber of Participants With Moderate to Severe UC With Endoscopic Remission as Defined by the MES

The endoscopic subscore evaluation for the MMS consisted of independent, blinded, central review of a high-resolution recorded video. The endoscopic subscore assessed disease activity from 0 (normal or inactive disease) to 3 (severe activity). Higher scores indicated more severe disease activity. Endoscopic remission was defined as a MES of 0 at Week 14.

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC With Endoscopic Remission as Defined by the MES
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC With Endoscopic Remission as Defined by the MES388
SecondaryNumber of Participants With Moderate to Severe UC With a Clinical Response as Defined by 2-item Patient-reported Outcome (PRO2) Score

The PRO2-UC score was derived from 2 parameters from the MMS: stool frequency and rectal bleeding, recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Each parameter ranged from 0 (normal) to 3 (severe) with each subscore representing an average over the preceding 7 days. The total score was the summation of the subscores and therefore ranged from 0 (normal or inactive disease) to 6 (severe activity), where higher scores indicated more severe disease activity. Clinical response was defined as decrease from baseline of at least 50% in PRO2 (stool frequency and rectal bleeding) at Week 14.

Time frame:
Baseline to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by 2-item Patient-reported Outcome (PRO2) Score
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC With a Clinical Response as Defined by 2-item Patient-reported Outcome (PRO2) Score223934
SecondaryNumber of Participants With Moderate to Severe UC With a Clinical Remission as Defined by PRO2 Score

The PRO2-UC score was derived from 2 parameters from the MMS: stool frequency and rectal bleeding, recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Each parameter ranged from 0 (normal) to 3 (severe) with each subscore representing an average over the preceding 7 days. The total score was the summation of the subscores and therefore ranged from 0 (normal or inactive disease) to 6 (severe activity), where higher scores indicated more severe disease activity. Clinical remission was defined as score of stool frequency = 0 and rectal bleeding = 0 on the PRO2 scale at Week 14.

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe UC With a Clinical Remission as Defined by PRO2 Score
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)
Number of Participants With Moderate to Severe UC With a Clinical Remission as Defined by PRO2 Score41411
SecondaryNumber of Participants With Moderate to Severe CD With an Endoscopic Response as Defined by the Modified Multiplier-Simple Endoscopic Score (MM-SES-CD)

The MM-SES-CD is an endoscopic scoring tool that considers each individual parameter's prognostic value for achieving endoscopic remission while on active therapy. The SES-CD assesses the following 4 components: presence of ulcers, percentage of ulcerated surfaces, affected surface, and presence of strictures. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components was assessed in the 5 segments: the rectum, sigmoid and left colon, transverse colon, right colon, and ileum. The SES-CD was the sum of the individual scores of each of the components across the 5 segments. The range of SES-CD scores was 0 (none) - 12 (severe) for each segment, and 0 (none) - 60 (severe) for the overall SES-CD score, with higher scores indicating a greater degree of inflammation. Endoscopic response was defined as a decrease in MM-SES-CD of ≥50% from baseline at Week 14.

Time frame:
Baseline to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD With an Endoscopic Response as Defined by the Modified Multiplier-Simple Endoscopic Score (MM-SES-CD)
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Number of Participants With Moderate to Severe CD With an Endoscopic Response as Defined by the Modified Multiplier-Simple Endoscopic Score (MM-SES-CD)61618
SecondaryNumber of Participants With Moderate to Severe CD With a Clinical Response as Defined by Crohn's Disease Activity Index (CDAI) Score

The CDAI score consisted of an adjusted composite sum of 8 parameters, including daily diary evaluation for severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight, and hematocrit. The subscores of abdominal pain (0 \[no pain\] to 3 \[worst pain\]), general well-being (0 \[well\] to 4 \[terrible\]), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score that ranged from 0 (none) to 600 (severe) with a higher score indicating a worse outcome. Clinical response was defined as a ≥100-point decrease in CDAI score from baseline.

Time frame:
Baseline to Weeks 4, 8, 12 and 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD With a Clinical Response as Defined by Crohn's Disease Activity Index (CDAI) Score
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Week 4152418
Week 8193025
Week 12223131
Week 14243030
SecondaryNumber of Participants With Moderate to Severe CD With a Clinical Remission as Defined by CDAI Score

The CDAI score consisted of an adjusted composite sum of 8 parameters, including daily diary evaluation for severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight, and hematocrit. The subscores of abdominal pain (0 \[no pain\] to 3 \[worst pain\]), general well-being (0 \[well\] to 4 \[terrible\]), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score that ranged from 0 (none) to 600 (severe) with a higher score indicating a worse outcome. Clinical remission was defined as a CDAI score \<150 at Week 14.

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by CDAI Score
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by CDAI Score192325
SecondaryNumber of Participants With Moderate to Severe CD With a Clinical Response as Defined by PRO2-CD Score

The PRO2-CD score was the sum of the daily stool frequency subscore (0 \[normal\] to 3 \[severe\]) and abdominal pain subscore (0 \[no pain\] to 3 \[worst pain\]) from the CDAI. Total PRO2-CD score ranged from 0 (normal) - 6 (severe), with higher scores indicating more severe disease. These were recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Clinical response was defined as a decrease from baseline of at least 50% in PRO2-CD (abdominal pain and stool frequency) at Week 14.

Time frame:
Baseline to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD With a Clinical Response as Defined by PRO2-CD Score
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Number of Participants With Moderate to Severe CD With a Clinical Response as Defined by PRO2-CD Score81614
SecondaryNumber of Participants With Moderate to Severe CD With a Clinical Remission as Defined by PRO2-CD Score

The PRO2-CD score was the sum of the daily stool frequency subscore (0 \[normal\] to 3 \[severe\]) and abdominal pain subscore (0 \[no pain\] to 3 \[worst pain\]) from the CDAI. Total PRO2-CD score ranged from 0 (normal) - 6 (severe), with higher scores indicating more severe disease. These were recorded daily by the participant using a handheld electronic diary over each of the preceding 7 days. Clinical remission was defined as abdominal pain ≤1 and stool frequency ≤3 on the PRO2-CD scale at Week 14

Time frame:
Week 14
Reported as:
Count of participants · Participants
Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by PRO2-CD Score
ParticipantsPlacebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)
Number of Participants With Moderate to Severe CD With a Clinical Remission as Defined by PRO2-CD Score121717
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered TEAEs if onset occurred on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline (Day 1) up to Week 18
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)23232022231202
SecondaryNumber of Participants Who Stopped Taking the Investigational Medicinal Product (IMP) Due to AEs

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline (Day 1) up to Week 18
Reported as:
Count of participants · Participants
Number of Participants Who Stopped Taking the Investigational Medicinal Product (IMP) Due to AEs
ParticipantsPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Number of Participants Who Stopped Taking the Investigational Medicinal Product (IMP) Due to AEs20101410
SecondaryNumber of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs)

Treatment-emergent ADA positive: - the participant had a positive ADA sample (after first dose of study drug) but not at baseline (prior to first dose of study drug), or - the participant had a positive ADA sample at baseline (prior to first dose of study drug) and at the visit (after first dose of study drug), with at least a 4-fold increase in titer level.

Time frame:
Weeks 2, 4, 8, 14, and 18
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs)
ParticipantsTEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Week 2000410
Week 4020200
Week 8000000
Week 14000000
Week 18100000
SecondaryNumber of ADA Positive Participants With the Presence of Neutralizing ADA

Treatment-emergent ADA positive: - the participant had a positive ADA sample (after first dose of study drug) but not at baseline (prior to first dose of study drug), or - the participant had a positive ADA sample at baseline (prior to first dose of study drug) and at the visit (after first dose of study drug), with at least a 4-fold increase in titer level.

Time frame:
Weeks 2, 4, 8, 14, and 18
Reported as:
Count of participants · Participants
Number of ADA Positive Participants With the Presence of Neutralizing ADA
ParticipantsTEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Week 2000000
Week 4000000
Week 8000000
Week 14000000
Week 18100000

Adverse events

Collected over Baseline (Day 1) up to Week 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (UC)0/44 (0%)1/44 (2.3%)6/44 (13.6%)
TEV-48574 450 mg (UC)0/47 (0%)0/47 (0%)10/47 (21.3%)
TEV-48574 900 mg (UC)0/46 (0%)1/46 (2.2%)6/46 (13%)
TEV-48574 1800 mg (UC)0/7 (0%)0/7 (0%)2/7 (28.6%)
Placebo (CD)0/46 (0%)5/46 (10.9%)9/46 (19.6%)
TEV-48574 450 mg (CD)0/46 (0%)6/46 (13%)9/46 (19.6%)
TEV-48574 900 mg (CD)0/46 (0%)1/46 (2.2%)5/46 (10.9%)
TEV-48574 1800 mg (CD)0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
Haemorrhage intracranialNervous system disorders1/440/470/460/70/460/460/460/3
LeukocytosisBlood and lymphatic system disorders0/440/470/460/70/461/460/460/3
Atrial fibrillationCardiac disorders0/440/470/460/70/461/460/460/3
Coronary artery diseaseCardiac disorders0/440/470/460/70/461/460/460/3
Abdominal painGastrointestinal disorders0/440/470/460/70/460/461/460/3
Crohn's diseaseGastrointestinal disorders0/440/470/460/71/460/460/460/3
Food poisoningGastrointestinal disorders0/440/470/460/70/461/460/460/3
Intestinal perforationGastrointestinal disorders0/440/470/460/71/460/460/460/3
NauseaGastrointestinal disorders0/440/470/460/71/460/460/460/3
Rectal haemorrhageGastrointestinal disorders0/440/470/460/71/460/460/460/3
Most frequent other events
Most frequent other events
EventPlacebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)
InfluenzaInfections and infestations1/440/472/460/71/461/460/461/3
ProteinuriaRenal and urinary disorders0/440/471/460/70/460/460/461/3
EczemaSkin and subcutaneous tissue disorders0/440/470/460/70/460/460/461/3
InsomniaPsychiatric disorders0/440/471/461/70/460/460/460/3
Abnormal uterine bleedingReproductive system and breast disorders0/440/470/461/70/460/460/460/3
HeadacheNervous system disorders2/440/472/460/71/464/461/460/3
AnaemiaBlood and lymphatic system disorders3/441/471/460/71/463/460/460/3
NasopharyngitisInfections and infestations1/443/470/460/73/462/463/460/3
VomitingGastrointestinal disorders0/443/470/460/72/460/461/460/3
Upper respiratory tract infectionInfections and infestations1/443/471/460/72/460/460/460/3

Baseline characteristics

The intent-to-treat (ITT) analysis set for each indication (UC or CD) included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Mean42.2 ± 13.0838.7 ± 12.9942.1 ± 13.1940.9 ± 16.2438.3 ± 15.1342.5 ± 15.0838.1 ± 13.5843.7 ± 23.5440.4 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Female14181952419161116
Male30292722227312170
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Hispanic or Latino211002006
Not Hispanic or Latino42464574643463278
Unknown or Not Reported000001102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Race — Asian111001206
Race — Black or African American010010204
Race — White43444574545413273
Race — Other010000102
Race — Not Reported000000101
Modified Mayo Score (MMS)
Modified Mayo Score (MMS)(units on a scale)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Mean6.8 ± 1.166.6 ± 1.156.8 ± 1.116.6 ± 1.13————6.7 ± 1.14
Simple Endoscopic Score for Crohn's Disease (SES-CD)
Simple Endoscopic Score for Crohn's Disease (SES-CD)(units on a scale)Placebo (UC)TEV-48574 450 mg (UC)TEV-48574 900 mg (UC)TEV-48574 1800 mg (UC)Placebo (CD)TEV-48574 450 mg (CD)TEV-48574 900 mg (CD)TEV-48574 1800 mg (CD)Total
Mean————12.0 ± 5.7012.7 ± 6.6412.1 ± 5.817.7 ± 2.8912.1 ± 6.01
08

Study locations

164 sites
  • Teva Investigational Site 15568
    Sun City, Arizona 85351, United States
  • Teva Investigational Site 15556
    San Diego, California 92103, United States
  • Teva Investigational Site 15747
    San Diego, California 92103, United States
  • Teva Investigational Site 15357
    Kissimmee, Florida 34741, United States
  • Teva Investigational Site 15563
    Miami, Florida 33032, United States
  • Teva Investigational Site 15365
    Miami, Florida 33136, United States
  • Teva Investigational Site 15748
    Miami, Florida 33176, United States
  • Teva Investigational Site 15375
    Orlando, Florida 32803, United States
  • Teva Investigational Site 15359
    Pinellas Park, Florida 33781, United States
  • Teva Investigational Site 15566
    Glenview, Illinois 60026, United States
  • Teva Investigational Site 15567
    Gurnee, Illinois 60031, United States
  • Teva Investigational Site 15574
    New Albany, Indiana 47150, United States
  • Teva Investigational Site 15362
    Iowa City, Iowa 52242, United States
  • Teva Investigational Site 15367
    Kansas City, Kansas 66160, United States
  • Teva Investigational Site 15368
    Louisville, Kentucky 40202, United States
  • Teva Investigational Site 15575
    Louisville, Kentucky 40218, United States
  • Teva Investigational Site 15363
    Columbia, Maryland 21045, United States
  • Teva Investigational Site 15358
    Liberty, Missouri 64068, United States
  • Teva Investigational Site 15373
    St Louis, Missouri 63110, United States
  • Teva Investigational Site 15369
    Las Vegas, Nevada 89128., United States
  • Teva Investigational Site 15558
    North Massapequa, New York 11758, United States
  • Teva Investigational Site 15370
    Chapel Hill, North Carolina 27514, United States
  • Teva Investigational Site 15750
    Beavercreek, Ohio 45440, United States
  • Teva Investigational Site 15557
    Greenville, South Carolina 29607, United States
  • Teva Investigational Site 15573
    Cordova, Tennessee 38018, United States
  • Teva Investigational Site 15360
    Austin, Texas 78748, United States
  • Teva Investigational Site 15371
    Dallas, Texas 75246, United States
  • Teva Investigational Site 15569
    Garland, Texas 75044, United States
  • Teva Investigational Site 15559
    Harlingen, Texas 78550, United States
  • Teva Investigational Site 15366
    Katy, Texas 77494, United States
  • Teva Investigational Site 15743
    Lubbock, Texas 79424, United States
  • Teva Investigational Site 15372
    Pearland, Texas 77584, United States
  • Teva Investigational Site 15374
    San Antonio, Texas 78229, United States
  • Teva Investigational Site 15565
    Southlake, Texas 76092, United States
  • Teva Investigational Site 15361
    Tyler, Texas 75701, United States
  • Teva Investigational Site 15364
    Salt Lake City, Utah 84124, United States
  • Teva Investigational Site 33055
    Innsbruck, 6020, Austria
  • Teva Investigational Site 33056
    Vienna, 1090, Austria
  • Teva Investigational Site 37134
    Edegem, 2650, Belgium
  • Teva Investigational Site 37133
    Liège, 4000, Belgium
  • Teva Investigational Site 59243
    Gorna Oryahovitsa, 5100, Bulgaria
  • Teva Investigational Site 59198
    Pleven, 5803, Bulgaria
  • Teva Investigational Site 59197
    Sofia, 1618, Bulgaria
  • Teva Investigational Site 59199
    Sofia, 1680, Bulgaria
  • Teva Investigational Site 59196
    Sofia, 1784, Bulgaria
  • Teva Investigational Site 11257
    Winnipeg, Manitoba R3A 1R9, Canada
  • Teva Investigational Site 54221
    Brno, 615 00, Czechia
  • Teva Investigational Site 54222
    Klatovy, 339 01, Czechia
  • Teva Investigational Site 54241
    Prague, 140 00, Czechia
  • Teva Investigational Site 54220
    Slaný, 274 01, Czechia
  • Teva Investigational Site 54242
    Zábřeh, 78901, Czechia
  • Teva Investigational Site 35280
    Caen, 14000, France
  • Teva Investigational Site 35295
    Nantes, 44300, France
  • Teva Investigational Site 35277
    Nice, 06200, France
  • Teva Investigational Site 35279
    Saint-Priest-en-Jarez, 42270, France
  • Teva Investigational Site 81057
    Tbilisi, 0102, Georgia
  • Teva Investigational Site 81052
    Tbilisi, 0119, Georgia
  • Teva Investigational Site 81054
    Tbilisi, 0160, Georgia
  • Teva Investigational Site 81056
    Tbilisi, 0178, Georgia
  • Teva Investigational Site 81053
    Tbilisi, 0180, Georgia
  • Teva Investigational Site 81055
    Tbilisi, 0180, Georgia
  • Teva Investigational Site 32796
    Berlin, 10318, Germany
  • Teva Investigational Site 32872
    Berlin, 12559, Germany
  • Teva Investigational Site 32873
    Duisburg, 47055, Germany
  • Teva Investigational Site 32793
    Kiel, 24105, Germany
  • Teva Investigational Site 32797
    Leipzig, 04103, Germany
  • Teva Investigational Site 32795
    Tübingen, 72076, Germany
  • Teva Investigational Site 32794
    Ulm, 89081, Germany
  • Teva Investigational Site 32874
    Wipperfürth, 51688, Germany
  • Teva Investigational Site 51334
    Budapest, 1085, Hungary
  • Teva Investigational Site 51335
    Budapest, H-1033, Hungary
  • Teva Investigational Site 51336
    Gyöngyös, 3200, Hungary
  • Teva Investigational Site 51333
    Székesfehérvár, H-8000, Hungary
  • Teva Investigational Site 51338
    Vác, H-2600, Hungary
  • Teva Investigational Site 80179
    Afula, 1834111, Israel
  • Teva Investigational Site 80191
    Beersheba, 8410101, Israel
  • Teva Investigational Site 80184
    Holon, 58100, Israel
  • Teva Investigational Site 80182
    Kfar Saba, 4428164, Israel
  • Teva Investigational Site 80180
    Rehovot, 7661041, Israel
  • Teva Investigational Site 30304
    Brescia, 25123, Italy
  • Teva Investigational Site 30285
    Milan, 20132, Italy
  • Teva Investigational Site 30286
    Milan, 20157, Italy
  • Teva Investigational Site 30284
    Rozzano, 20089, Italy
  • Teva Investigational Site 30303
    San Donato Milanese, 20097, Italy
  • Teva Investigational Site 30300
    San Giovanni Rotondo, 71013, Italy
  • Teva Investigational Site 30301
    Turin, 10128, Italy
  • Teva Investigational Site 84112
    Fukuoka, 814-0180, Japan
  • Teva Investigational Site 84110
    Kashiwa, 277-0871, Japan
  • Teva Investigational Site 84117
    Minato, 108-8642, Japan
  • Teva Investigational Site 84115
    Mitaka, 181-8611, Japan
  • Teva Investigational Site 84118
    Nagoya, 457-8511, Japan
  • Teva Investigational Site 84113
    Osaka, 530-0011, Japan
  • Teva Investigational Site 84114
    Sakura, 285-8741, Japan
  • Teva Investigational Site 84116
    Shinjuku, 169-0073, Japan
  • Teva Investigational Site 84111
    Toyama, 930-8550, Japan
  • Teva Investigational Site 41015
    Lorenskog, 1478, Norway
  • Teva Investigational Site 41014
    Tromsø, 9038, Norway
  • Teva Investigational Site 53565
    Bydgoszcz, 85-794, Poland
  • Teva Investigational Site 53542
    Częstochowa, 42-202, Poland
  • Teva Investigational Site 53543
    Elblag, 82-300, Poland

Showing the first 100 of 164 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Reinisch W, Stepek D, Kempinski R, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Jairath V. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00120-2. doi: 10.1016/S2468-1253(26)00120-2. Online ahead of print. PubMed 42462750 ↗
  • Jairath V, Kierkus J, Duvall GA, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Reinisch W. Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00119-6. doi: 10.1016/S2468-1253(26)00119-6. Online ahead of print. PubMed 42462749 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05499130
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
Sep 30, 2022
Primary completion
Nov 12, 2024
Completion
Nov 12, 2024
Results posted
Dec 5, 2025
Last update
Mar 27, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvakitug

Start the discussion